(REPL) Replimune - Overview
Stock: Oncolytic Immunotherapy, RP1, RP2, RP3, Cancer Treatment
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 97.0% |
| Relative Tail Risk | -23.1% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.62 |
| Alpha | -59.28 |
| Character TTM | |
|---|---|
| Beta | 0.828 |
| Beta Downside | 1.562 |
| Drawdowns 3y | |
|---|---|
| Max DD | 88.75% |
| CAGR/Max DD | -0.37 |
Description: REPL Replimune December 25, 2025
Replimune Group, Inc. (NASDAQ: REPL) is a clinical-stage biotech that develops oncolytic immunotherapy viruses designed to turn tumors into in-situ vaccines, thereby stimulating a systemic anti-cancer immune response.
The lead candidate, RP1, is a genetically engineered HSV-1 virus that expresses the GALV-GP R(-) envelope protein and human GM-CSF, targeting a broad portfolio of solid tumors. Follow-on programs include RP2, which delivers an anti-CTLA-4 antibody-like fragment to locally block checkpoint inhibition, and RP3, engineered to secrete additional T-cell-activating cytokines.
As of the most recent quarterly filing (Q3 2024), Replimune reported cash and cash equivalents of approximately $45 million, a net loss of $12 million for the quarter, and a cash burn rate of roughly $4 million per month, implying runway through mid-2025 assuming no additional financing.
The oncolytic virus market is projected to grow at a CAGR of 12-15 % through 2030, driven by increasing FDA approvals for viral immunotherapies and rising investor appetite for combination-immuno-oncology strategies; however, the company’s valuation remains highly sensitive to the outcomes of its Phase 1/2 trials and the ability to secure partnership funding.
For a deeper, data-driven assessment of REPL’s risk-adjusted upside, you may find the analyst tools on ValueRay worth exploring.
Piotroski VR‑10 (Strict, 0-10) 0.0
| Net Income: -310.3m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.69 > 0.02 and ΔFCF/TA -31.45 > 1.0 |
| NWC/Revenue: 19.1k% < 20% (prev 9868 %; Δ 9212 % < -1%) |
| CFO/TA -0.67 > 3% & CFO -262.7m > Net Income -310.3m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 6.31 > 1.5 & < 3 |
| Outstanding Shares: last quarter (91.9m) vs 12m ago 16.99% < -2% |
| Gross Margin: -138.7% > 18% (prev 0.26%; Δ -13.9k% > 0.5%) |
| Asset Turnover: 0.33% > 50% (prev 0.81%; Δ -0.48% > 0%) |
| Interest Coverage Ratio: -48.02 > 6 (EBITDA TTM -308.4m / Interest Expense TTM 6.48m) |
Altman Z'' -15.00
| A: 0.72 (Total Current Assets 333.7m - Total Current Liabilities 52.9m) / Total Assets 389.4m |
| B: -2.87 (Retained Earnings -1.12b / Total Assets 389.4m) |
| C: -0.70 (EBIT TTM -311.0m / Avg Total Assets 443.8m) |
| D: -8.83 (Book Value of Equity -1.11b / Total Liabilities 126.1m) |
| Altman-Z'' Score: -18.61 = D |
Beneish M -1.92
| DSRI: 2.42 (Receivables 1.81m/2.05m, Revenue 1.47m/4.04m) |
| GMI: 1.00 (fallback, negative margins) |
| AQI: 1.87 (AQ_t 0.01 / AQ_t-1 0.01) |
| SGI: 0.36 (Revenue 1.47m / 4.04m) |
| TATA: -0.12 (NI -310.3m - CFO -262.7m) / TA 389.4m) |
| Beneish M-Score: -1.92 (Cap -4..+1) = B |
What is the price of REPL shares?
Over the past week, the price has changed by +10.24%, over one month by -8.28%, over three months by -8.82% and over the past year by -44.88%.
Is REPL a buy, sell or hold?
- StrongBuy: 3
- Buy: 5
- Hold: 0
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the REPL price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 12.6 | 62.2% |
| Analysts Target Price | 12.6 | 62.2% |
| ValueRay Target Price | 5.8 | -25.4% |
REPL Fundamental Data Overview February 03, 2026
Revenue TTM = 1.47m USD
EBIT TTM = -311.0m USD
EBITDA TTM = -308.4m USD
Long Term Debt = 47.2m USD (from longTermDebt, last quarter)
Short Term Debt = 4.05m USD (from shortTermDebt, last quarter)
Debt = 76.3m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -26.0m USD (from netDebt column, last quarter)
Enterprise Value = 304.1m USD (551.5m + Debt 76.3m - CCE 323.6m)
Interest Coverage Ratio = -48.02 (Ebit TTM -311.0m / Interest Expense TTM 6.48m)
EV/FCF = -1.13x (Enterprise Value 304.1m / FCF TTM -269.7m)
FCF Yield = -88.67% (FCF TTM -269.7m / Enterprise Value 304.1m)
FCF Margin = -18.3k% (FCF TTM -269.7m / Revenue TTM 1.47m)
Net Margin = -21.1k% (Net Income TTM -310.3m / Revenue TTM 1.47m)
Gross Margin = -138.7% ((Revenue TTM 1.47m - Cost of Revenue TTM 3.51m) / Revenue TTM)
Gross Margin QoQ = none% (prev none%)
Tobins Q-Ratio = 0.78 (Enterprise Value 304.1m / Total Assets 389.4m)
Interest Expense / Debt = 0.68% (Interest Expense 518.0k / Debt 76.3m)
Taxrate = 21.0% (US default 21%)
NOPAT = -245.7m (EBIT -311.0m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 6.31 (Total Current Assets 333.7m / Total Current Liabilities 52.9m)
Debt / Equity = 0.29 (Debt 76.3m / totalStockholderEquity, last quarter 263.3m)
Debt / EBITDA = 0.08 (negative EBITDA) (Net Debt -26.0m / EBITDA -308.4m)
Debt / FCF = 0.10 (negative FCF - burning cash) (Net Debt -26.0m / FCF TTM -269.7m)
Total Stockholder Equity = 374.6m (last 4 quarters mean from totalStockholderEquity)
RoA = -69.91% (Net Income -310.3m / Total Assets 389.4m)
RoE = -82.83% (Net Income TTM -310.3m / Total Stockholder Equity 374.6m)
RoCE = -73.74% (EBIT -311.0m / Capital Employed (Equity 374.6m + L.T.Debt 47.2m))
RoIC = -58.34% (negative operating profit) (NOPAT -245.7m / Invested Capital 421.2m)
WACC = 7.94% (E(551.5m)/V(627.8m) * Re(8.97%) + D(76.3m)/V(627.8m) * Rd(0.68%) * (1-Tc(0.21)))
Discount Rate = 8.97% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 17.44%
Fair Price DCF = unknown (Cash Flow -269.7m)
EPS Correlation: 19.36 | EPS CAGR: 26.32% | SUE: 4.0 | # QB: 1
Revenue Correlation: 23.05 | Revenue CAGR: 0.0% | SUE: -0.70 | # QB: 0
EPS next Year (2027-03-31): EPS=-2.06 | Chg30d=+0.000 | Revisions Net=+0 | Growth EPS=+38.8% | Growth Revenue=+4406.0%